Supplementary table S1. Correlation between the SII and clinicopathological characteristics (training cohort, n=133 and validation cohort, n=123)
Variable / SII
Training cohort / Validation cohort
<330 / ≥330 / P-value / <330 / ≥330 / P-value
No. of patients / 80 / 53 / 82 / 41
Age (y) / ≤50 / 36 / 25 / 0.806 / 43 / 21 / 0.898
>50 / 44 / 28 / 39 / 20
Sex / Male / 66 / 46 / 0.506 / 78 / 37 / 0.518†
Female / 14 / 7 / 4 / 4
Liver cirrhosis / Yes / 72 / 38 / 0.006 / 68 / 26 / 0.016
No / 8 / 15 / 14 / 15
Child-Pugh / A / 80 / 52 / 0.398* / 82 / 40 / 0.333*
B / 0 / 1 / 0 / 1
HBsAg / Negative / 11 / 13 / 0.114 / 8 / 4 / 1.000†
Positive / 69 / 40 / 74 / 37
ALT (U/L) / ≤40 / 39 / 30 / 0.375 / 48 / 27 / 0.433
>40 / 41 / 23 / 34 / 14
AFP (ng/mL) / ≤20 / 38 / 21 / 0.371 / 27 / 10 / 0.330
>20 / 42 / 32 / 55 / 31
Tumor encapsulation / None / 37 / 23 / 0.746 / 26 / 20 / 0.065
Complete / 43 / 30 / 56 / 21
Tumor differentiation / I-II / 61 / 35 / 0.198 / 61 / 22 / 0.021
III-IV / 19 / 18 / 21 / 19
Tumor size (cm) / ≤5 / 68 / 30 / <0.001 / 65 / 15 / <0.001
>5 / 12 / 23 / 17 / 26
Tumor number / Single / 72 / 48 / 0.914 / 73 / 39 / 0.434†
Multiple / 8 / 5 / 9 / 2
Vascular invasion / Yes / 22 / 25 / 0.020 / 24 / 21 / 0.434†
No / 58 / 28 / 58 / 20
BCLC / 0+A / 58 / 24 / 0.002 / 68 / 33 / 0.739
B+C / 22 / 29 / 14 / 8
Early recurrence / No / 65 / 33 / 0.015 / 59 / 14 / <0.001
Yes / 15 / 20 / 23 / 27
* Fisher exact test
†Continuous correction
Abbreviations: HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; AFP, alpha-fetoprotein; BCLC, the Barcelona Clinic Liver Cancer staging; SII, systemic immune-inflammation index.

4

Supplementary table S2. Correlation Between SII, NLR and PLR and clinicopathological characteristics in training and validation cohorts
Variable / Training cohort / Validation cohort
NLR / PLR / NLR / PLR
<5 / ≥5 / P-value / <150 / ≥150 / P-value / <5 / ≥5 / P-value / <150 / ≥150 / P-value
No. of patients / 116 / 17 / 113 / 20 / 113 / 10 / 115 / 8
Age (y) / ≤50 / 50 / 11 / 0.095 / 50 / 11 / 0.374 / 58 / 6 / 0.845† / 59 / 5 / 0.805†
>50 / 66 / 6 / 63 / 9 / 55 / 4 / 56 / 3
Sex / Male / 98 / 14 / 1.000† / 94 / 18 / 0.662† / 106 / 9 / 0.503* / 108 / 7 / 0.426*
Female / 18 / 3 / 19 / 2 / 7 / 1 / 7 / 1
Liver cirrhosis / Yes / 96 / 14 / 1.000† / 99 / 11 / 0.001† / 89 / 5 / 0.096† / 90 / 4 / 0.164†
No / 20 / 3 / 14 / 9 / 24 / 5 / 25 / 4
Child-Pugh / A / 115 / 17 / 1.000* / 112 / 20 / 1.000* / 112 / 10 / 1.000* / 115 / 7 / 0.065*
B / 1 / 0 / 1 / 0 / 1 / 0 / 0 / 1
HBsAg / Negative / 20 / 4 / 0.770† / 17 / 7 / 0.068† / 11 / 1 / 1.000* / 11 / 1 / 0.571*
Positive / 96 / 13 / 96 / 13 / 102 / 9 / 104 / 7
ALT (U/L) / ≤40 / 64 / 5 / 0.047 / 58 / 11 / 0.762 / 69 / 6 / 1.000† / 71 / 4 / 0.777†
>40 / 52 / 12 / 55 / 9 / 44 / 4 / 44 / 4
AFP (ng/mL) / ≤20 / 53 / 6 / 0.420 / 50 / 9 / 0.950 / 35 / 2 / 0.715† / 35 / 2 / 1.000†
>20 / 63 / 11 / 63 / 11 / 78 / 8 / 80 / 6
Tumor encapsulation / None / 53 / 7 / 0.727 / 51 / 9 / 0.991 / 42 / 4 / 1.000† / 43 / 3 / 1.000†
Complete / 63 / 10 / 62 / 11 / 71 / 6 / 72 / 5
Tumor differentiation / I-II / 83 / 13 / 0.894† / 82 / 14 / 0.813 / 79 / 4 / 0.113† / 78 / 5 / 1.000†
III-IV / 33 / 4 / 31 / 6 / 34 / 6 / 37 / 3
Tumor size (cm) / ≤5 / 88 / 10 / 0.232† / 88 / 10 / 0.009 / 77 / 3 / 0.038† / 78 / 2 / 0.021†
>5 / 28 / 7 / 25 / 10 / 36 / 7 / 37 / 6
Tumor number / Single / 103 / 17 / 0.310† / 101 / 19 / 0.710† / 102 / 10 / 0.597* / 105 / 7 / 0.538*
Multiple / 13 / 0 / 12 / 1 / 11 / 0 / 10 / 1
Vascular invasion / Yes / 38 / 9 / 0.154 / 38 / 9 / 0.327 / 37 / 8 / 0.009† / 41 / 4 / 0.663†
No / 78 / 8 / 75 / 11 / 76 / 2 / 74 / 4
BCLC / 0+A / 75 / 7 / 0.063 / 72 / 10 / 0.245 / 93 / 8 / 1.000† / 95 / 6 / 0.947†
B+C / 41 / 10 / 41 / 10 / 20 / 2 / 20 / 2
* Fisher exact test
†Continuous correction
Abbreviations: HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; AFP, alpha-fetoprotein; BCLC, the Barcelona Clinic Liver Cancer staging; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio.

4

Supplemental Figure Legends：

Supplementary figure S1. The optimal cutoff value for the SII was selected by X-tile 3.6.1 software (Yale University, New Haven, CT, USA).

Supplementary figure S2. Kaplan-Meier analysis of OS and RFS for (A) NLR and (B) PLR in the training cohort; Predictive ability of the SII was compared with other clinical parameters and the AUCs with 95% CI for TTR in the training (C) and validation cohorts (D) are shown. (*, P<0.05 versus SII)

Supplementary figure S3. (A) Kaplan-Meier analysis of OS and RFS for NLR in the validation cohort; (B) Kaplan-Meier analysis of OS and RFS for PLR in the validation cohort.

4